ELAN Q2 2024 Earnings — Elanco Animal Health Incorporated Revenue & Financial Results | Market Cap Arena

ELANElanco Animal Health Incorporated

$12B

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.2B+12.0% YoY

Gross Profit

$558M47.1% margin

Operating Income

$115M9.7% margin

Net Income

-$50M-4.2% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

-1.7%

Cash Flow

Operating Cash Flow

$200M

Free Cash Flow

$166M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$13.8B

Total Liabilities

$7.8B

Stockholders' Equity

$5.9B

Cash & Equivalents

$416M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.2B	$1.1B	+12.0%
Gross Profit	$558M	$487M	+14.6%
Operating Income	$115M	$53M	+117.0%
Net Income	-$50M	-$97M	+48.5%

Revenue Segments

Farm Animal

$594M34%

Pet Health

$579M33%

Cattle

$257M15%

Poultry

$198M11%

Swine

$90M5%

Contract Manufacturing

$11M1%

Geographic Segments

Non-US

$641M54%

UNITED STATES

$543M46%